Key Insights

Highlights

Success Rate

60% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 65/100

Termination Rate

33.3%

2 terminated out of 6 trials

Success Rate

60.0%

-26.5% vs benchmark

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed with results

Key Signals

2 with results60% success

Data Visualizations

Phase Distribution

3Total

Not Applicable (1)

P 2 (1)

P 4 (1)

Trial Status

Completed3

Terminated2

Recruiting1

Trial Success Rate

60.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT07358910Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

NCT02736968Phase 2Completed

Auranofin for Giardia Protozoa

NCT02942485Phase 4TerminatedPrimary

Treatment of Giardia Lamblia Infections in Children

NCT00001162Terminated

Parasitic Infections of the Gastrointestinal Tract

NCT02105714Completed

Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders

NCT00607074Not ApplicableCompletedPrimary

Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh

Showing all 6 trials

Giardiasis